CUPERTINO, Calif., Feb. 7, 2011 /PRNewswire/ -- DURECT Corporation announced today that Matt Hogan (Chief Financial Officer) will be presenting at the BIO CEO & Investor Conference on Monday, February 14 at 9:30 a.m. Eastern Time. The conference is being held at the Waldorf-Astoria Hotel in New York City.
(Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO)
A live audio webcast of the presentation will be available by accessing DURECT's homepage at http://www.durect.com/ and clicking "Investor Relations." If you are unable to participate during the live webcast, the call will be archived on DURECT's website under Audio Archive in the "Investor Relations" section.
About DURECT Corporation
DURECT is an emerging specialty pharmaceutical company developing innovative drugs for pain and other chronic diseases, with late-stage development programs including REMOXY®, POSIDUR(TM), ELADUR(TM), and TRANSDUR®-Sufentanil. DURECT's proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs. For more information, please visit http://www.durect.com/.
NOTE: POSIDUR(TM), SABER(TM), ORADUR®, TRANSDUR®, and ELADUR(TM) are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners. REMOXY, POSIDUR, ELADUR and TRANSDUR-Sufentanil are drug candidates under development and have not been approved for commercialization by the U.S. Food and Drug Administration or other health authorities.
PRN Photo Desk, photodesk@prnewswire.com
DURECT Corporation
CONTACT: Matthew J. Hogan, Chief Financial Officer of DURECT,
+1-408-777-4936
Web Site: http://www.durect.com/
